Minerva Neurosciences (NERV) Total Liabilities (2013 - 2026)

Minerva Neurosciences' Total Liabilities history runs 14 years deep, the most recent figure standing at $343.1 million for Q1 2026.

• Quarterly Total Liabilities rose 453.83% year-over-year to $343.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $343.1 million (up 453.83% YoY) and the FY2025 annual result came in at $233.8 million, up 272.0% from the prior year.
• Total Liabilities was $343.1 million for Q1 2026 at Minerva Neurosciences, up from $233.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $343.1 million in Q1 2026 and bottomed at $61.9 million in Q1 2025.
• A 5-year average of $99.4 million and a median of $75.1 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2025 — Total Liabilities plunged 31.12% — and 2026, when it surged 453.83%.
• Minerva Neurosciences' Total Liabilities stood at $75.1 million in 2022, then climbed by 13.64% to $85.4 million in 2023, then fell by 26.38% to $62.8 million in 2024, then jumped by 272.0% to $233.8 million in 2025, then jumped by 46.77% to $343.1 million in 2026.
• Business Quant data shows NERV's Total Liabilities at $343.1 million in Q1 2026, $233.8 million in Q4 2025, and $62.7 million in Q3 2025.